BioCryst gets FDA approval for Orladeyo to prevent attacks in HAE patients
US-based BioCryst Pharmaceuticals has received the US Food and Drug Administration (FDA) approval for Orladeyo (berotralstat) to prevent attacks related to hereditary angioedema (HAE) in patients aged 12